Welcome on the DDIM-Website of Dr. Jan-Uwe Claas

 
User photo

Dr.

Jan-Uwe Claas

Expert Health Care & Pharma: Interim Management & Consulting

It’s not about ideas. It’s about making ideas happen.

from now
Interim Manager since: 01/2023
Update: 22.02.2024

Contact data

Grenzstr. 1
D-65375 Oestrich-Winkel
zbp.tavgyhfabp-fnnyp@fnnyp

Telefon Mobile
+49 151 12134245

Social networks

Personal data

Date of birth
23.11.1964 (Age:59)

Short profile

Intro
As an interim manager, Dr. Jan Claas supports companies in pharma, biotech and medtech to achieve higher growth and profit through the optimal positioning and market launch of innovative brands. "In the pre-launch and launch phase of an innovative product, the decisions is made for the long-term success of the brand that cannot be corrected later." 
Dr. Claas has fifteen years of experience as national and international marketing expert up to the position of Senior VP International Marketing as well as ten years of experience as Managing Director of European country organizations. In addition companies benefit from his experience in leading complex organizations and his track record in successfully executing transformation processes and turnarounds.
Experience overview
  • Successful General Management roles with full P&L- and BD-responsibility
  • Extensive experience in restructuring, transforming and building up of new organizations
  • Deep knowledge of the pharmaceutical, biotechnology and life science industry
  • In-depth experience in driving organisational turn arounds & improvement of efficiency
  • Successful leadership of up to 250 employees with multinational background
  • National & international launch of innovations including responsibility for commercial development
  • Coaching and consulting of Start-Up enterprises in health care

IM projects (self employed)


Company description

The company is a leading European pharmaceutical company specialised in the treatment of central nervous system (CNS) disorders

Company turnover in Mio $
500 Mio USD
Number of employees in company
1000
City / place
Langenfeld

Work history (permanent employment)

City / place
Deutschland / EU
Remarks
Building up & leading a country region consisting of the smaller/mid sized EU countries (CH, AT, BE, NL, LUX, DK, SE, NO, FI, IE, PT).
Full responsibility for the profit & loss as well as the personell of the region & country organisations.
Doubling of profitability of the EU-Cluster from 25% to 50%
Employees: 250
Sales volume: 200 M€
City / place
Deutschland
Remarks
Responsible for marketing, commercial excellence and digital strategy for all Grünenthal brands with a special focus on 2 new product launches.
Employees: 37
City / place
United Kingdom
Remarks
Full responsibility for the profit & loss as well as the personell of the organisation.
Restructuring in the UK organisation to achieve a turnaround of the operative business.
Increase of profitability from -23% in 2011 to +33% in 2016.
Employees: 180
Sales volume: 100 M €
City / place
Deutschland
Remarks
Responsible for marketing strategy and central marketing budget for all brands/products
Most successful product launch in company history: Brand is today Grünenthal's key sales & profit driver
Employees: 21
City / place
Deutschland
Remarks
Responsible for preparation of most important international brand launch in company history in close collaboration with all country organisations
Employees: 11
City / place
Deutschland
Remarks
Responsible for global marketing of all strong analgesics in the market and in clinical development as well as commercial lead of an international collaboration with J&J
Employees: 8
City / place
Deutschland
Remarks
Responsible for global marketing of all analgesics in clinical development as well as commercial lead of an international collaboration with J&J
Employees: 3
City / place
Deutschland
Remarks
Responsible for the marketing strategy in the German market and the launch of new products
Employees: 8
City / place
Deutschland
Remarks
Responsible for all marketing activities for Janssen-Cilag's key brand (treatment of Schizophrenia)
Employees: 0
City / place
Deutschland
Remarks
Responsible for the Medical Marketing Strategy Oncology and the initiation and management of Investigator initiated Clinical Studies (IITs)
Employees: 3
City / place
Deutschland
Remarks
Responsible for Medical Marketing Germany
Employees: 0
City / place
Deutschland
Remarks
Responsible for Scientific Marketing
Employees: 0

Education

Loading, please be patient...